{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:43:24Z","timestamp":1790109804388,"version":"4.0.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11926-016-0580-1","type":"journal-article","created":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T23:03:29Z","timestamp":1461711809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of Small Vessel Vasculitides"],"prefix":"10.1007","volume":"18","author":[{"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Anelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"580_CR1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","volume":"337","author":"JC Jennette","year":"1997","unstructured":"Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512\u201323.","journal-title":"N Engl J Med"},{"key":"580_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311. This paper represents the latest effort to improve nomenclature, to change names and definitions as appropriate, and to add important categories of vasculitis that were not included in the first International Chapel Hill Consensus Conference.","journal-title":"Arthritis Rheum"},{"key":"580_CR3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"5091","key":"580_CR4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","volume":"2","author":"EW Walton","year":"1958","unstructured":"Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958;2(5091):265\u201370.","journal-title":"Br Med J"},{"key":"580_CR5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310\u20137.","journal-title":"Ann Rheum Dis"},{"key":"580_CR6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg\u2013Strauss Syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17\u201328.","journal-title":"Medicine (Baltimore)"},{"key":"580_CR7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827\u201332.","journal-title":"Ann Rheum Dis"},{"key":"580_CR8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.autrev.2012.08.007","volume":"12","author":"JU Holle","year":"2013","unstructured":"Holle JU, Gross WL. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev. 2013;12:483\u20136. This article summarizes the current evidence for the use of conventional therapy and biologics in ANCA-associated vasculitis.","journal-title":"Autoimmun Rev"},{"key":"580_CR9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","volume":"84","author":"M Walsh","year":"2013","unstructured":"Walsh M, Casian A, Flossmann O, Westman K, H\u00f6glund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84:397\u2013402. This study evaluates a comparison between plasma exchange and intravenous methylprednisolone in improving renal disease.","journal-title":"Kidney Int"},{"key":"580_CR10","first-page":"14","volume":"73","author":"M Walsh","year":"2013","unstructured":"Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;73:14. A trial to determine whether plasma exchange as well as immunosuppressive therapy are effective in reducing death and end-stage renal disease in ANCA-associated vasculitis.","journal-title":"Trials"},{"key":"580_CR11","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K Groot De","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461\u20139.","journal-title":"Arthritis Rheum"},{"key":"580_CR12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.lpm.2013.02.067","volume":"42","author":"RB Jones","year":"2013","unstructured":"Jones RB, Harper L, Ballarin J, Brogan P, Bruchfeld A, et al. A randomised trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA associated vasculitis. Presse Med. 2013;42:678. These preliminary data attest that mycophenolate mofetil is effective as intravenous cyclophosphamide pulses for induction of remission.","journal-title":"Presse Med"},{"key":"580_CR13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.autrev.2014.08.017","volume":"13","author":"C Comarmond","year":"2014","unstructured":"Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13:1121\u20135.","journal-title":"Autoimmun Rev"},{"key":"580_CR14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux C, Qu\u00e9m\u00e9neur T, Ninet J, Diot E, Kyndt X, de Wazi\u00e8res B, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67:1117\u201327. New therapeutic strategy for induction of remission in older patients with systemic necrotizing vasculitides, capable of reducing serious adverse events within the first 3\u00a0years of follow-up.","journal-title":"Arthritis Rheumatol"},{"key":"580_CR15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K Groot de","year":"2009","unstructured":"de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670\u201380.","journal-title":"Ann Intern Med"},{"key":"580_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115\u201323.","journal-title":"Semin Hematol"},{"key":"580_CR17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"580_CR18","first-page":"57","volume":"164","author":"RB Jones","year":"2011","unstructured":"Jones RB, Walsh M, Jayne DRW, On behalf of the European Vasculitis Study Group. Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin Exp Immunol. 2011;164 Suppl 1:57\u20138.","journal-title":"Clin Exp Immunol"},{"key":"580_CR19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"580_CR20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417\u201327. A single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remission over the course of 18 months.","journal-title":"N Engl J Med"},{"issue":"1 Suppl 64","key":"580_CR21","first-page":"S63","volume":"29","author":"M Menthon de","year":"2011","unstructured":"de Menthon M, Cohen P, Pagnoux C, Buchler M, Sibilia J, D\u00e9tr\u00e9e F, et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S63\u201371.","journal-title":"Clin Exp Rheumatol"},{"key":"580_CR22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","volume":"15","author":"A Booth","year":"2004","unstructured":"Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNF(alpha) blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15:717\u201321.","journal-title":"J Am Soc Nephrol"},{"key":"580_CR23","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.0000124720.18538.DD","volume":"109","author":"AD Booth","year":"2004","unstructured":"Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718\u201323.","journal-title":"Circulation"},{"key":"580_CR24","doi-asserted-by":"crossref","first-page":"c89","DOI":"10.1159\/000319655","volume":"117","author":"MD Morgan","year":"2011","unstructured":"Morgan MD, Drayson MT, Savage CO, Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract. 2011;117:c89\u201397.","journal-title":"Nephron Clin Pract"},{"key":"580_CR25","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/ndt\/gfq187","volume":"25","author":"S Laurino","year":"2010","unstructured":"Laurino S, Chaudhry A, Booth A, Conte G, Jayne D. Prospective study of TNF-alpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant. 2010;25:3307\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"580_CR26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","volume":"73","author":"CA Langford","year":"2014","unstructured":"Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis. 2014;73:1376\u20139. The first report of an open-label trial of abatacept in non-severe relapsing granulomatosis with polyangiitis.","journal-title":"Ann Rheum Dis"},{"key":"580_CR27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","volume":"45","author":"A Berti","year":"2015","unstructured":"Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, et al. Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. Semin Arthritis Rheum. 2015;45:48\u201354. The finding of an activated IL-6 pathway in patients with ANCA-associated vasculitis provides a rationale for the successful treatment with tocilizumab.","journal-title":"Semin Arthritis Rheum"},{"key":"580_CR28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10067-013-2457-2","volume":"33","author":"K Takenaka","year":"2014","unstructured":"Takenaka K, Ohba T, Suhara K, Sato Y, Nagasaka K. Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab. Clin Rheumatol. 2014;33:287\u20139.","journal-title":"Clin Rheumatol"},{"key":"580_CR29","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/rheumatology\/ker222","volume":"50","author":"K Sumida","year":"2011","unstructured":"Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E. Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford). 2011;50:1928\u201330.","journal-title":"Rheumatology (Oxford)"},{"key":"580_CR30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1681\/ASN.2010080892","volume":"23","author":"A Schreiber","year":"2012","unstructured":"Schreiber A, Pham CT, Hu Y, Schneider W, Luft FC, Kettritz R. Neutrophil serine proteases promote IL-1\u03b2 generation and injury in necrotizing crescentic glomerulonephritis. J Am Soc Nephrol. 2012;23:470\u201382.","journal-title":"J Am Soc Nephrol"},{"key":"580_CR31","doi-asserted-by":"crossref","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","volume":"34","author":"M Chen","year":"2010","unstructured":"Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276\u201386.","journal-title":"J Autoimmun"},{"issue":"S2","key":"580_CR32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/annrheumdis-2014-eular.3728","volume":"73","author":"DR Jayne","year":"2014","unstructured":"Jayne DR, Bruchfeld A, Schaier M, Ciechanowski K, Harper L, Jadoul M, et al. Oral C5A receptor antagonist CCX168 phase 2 clinical trial in ANCA-associated renal vasculitis. Ann Rheum Dis. 2014;73(S2):148. The most recent report that supports CCX168 efficacy combined with cyclophosphamide for the management of ANCA-associated renal vasculitis.","journal-title":"Ann Rheum Dis"},{"key":"580_CR33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadonien\u00e9 J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36\u201344.","journal-title":"N Engl J Med"},{"key":"580_CR34","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304:2381\u20138.","journal-title":"JAMA"},{"key":"580_CR35","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. AZA or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790\u2013803.","journal-title":"N Engl J Med"},{"key":"580_CR36","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","volume":"46","author":"C Metzler","year":"2007","unstructured":"Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology. 2007;46:1087\u201391.","journal-title":"Rheumatology"},{"key":"580_CR37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2169\/internalmedicine.42.771","volume":"42","author":"ER Popa","year":"2003","unstructured":"Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med. 2003;42:771\u201380.","journal-title":"Intern Med"},{"key":"580_CR38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16\u201320.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"580_CR39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","volume":"14","author":"K Zycinska","year":"2009","unstructured":"Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009;14 Suppl 4:265\u20137.","journal-title":"Eur J Med Res"},{"key":"580_CR40","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/ard.2010.130203","volume":"69","author":"JU Holle","year":"2010","unstructured":"Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, et al. Prospective long-term follow-up of patients with localized Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis. 2010;69:1934\u20139.","journal-title":"Ann Rheum Dis"},{"key":"580_CR41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3899\/jrheum.100518","volume":"38","author":"C Pagnoux","year":"2011","unstructured":"Pagnoux C, Stubbe M, Lifermann F, Decaux O, Pavic C, B\u00e9rezn\u00e9, et al. Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J Rheumatol. 2011;38:475\u20138.","journal-title":"J Rheumatol"},{"key":"580_CR42","doi-asserted-by":"crossref","first-page":"11379","DOI":"10.1016\/0140-6736(91)92797-6","volume":"337","author":"DR Jayne","year":"1991","unstructured":"Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991;337:11379.","journal-title":"Lancet"},{"key":"580_CR43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","volume":"336","author":"DR Jayne","year":"1993","unstructured":"Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol. 1993;336:469\u201372.","journal-title":"Adv Exp Med Biol"},{"key":"580_CR44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DR Jayne","year":"2000","unstructured":"Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93:433\u20139.","journal-title":"QJM"},{"key":"580_CR45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","volume":"58","author":"V Martinez","year":"2008","unstructured":"Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308\u201317.","journal-title":"Arthritis Rheum"},{"key":"580_CR46","author":"E Crickx","year":"2015","unstructured":"Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as immunomodulating agent in ANCA-associated vasculitides: a French nationwide study of 92 patients. Arthritis Rheumatol. 2015. doi: 10.1002\/art.39472 . The most recent study that shows the clinical benefit of intravenous immunoglobulin as adjunctive therapy for treating ANCA-associated vasculitides.","journal-title":"Arthritis Rheumatol"},{"key":"580_CR47","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3760\u20139.","journal-title":"Arthritis Rheum"},{"key":"580_CR48","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380. In the present study, rituximab was superior to azathioprine to maintain remission of ANCA-associated vasculitis.","journal-title":"N Engl J Med"},{"key":"580_CR49","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149\u201354.","journal-title":"Arthritis Rheum"},{"key":"580_CR50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351\u201361.","journal-title":"N Engl J Med"},{"key":"580_CR51","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.30394","volume":"63","author":"F Silva","year":"2011","unstructured":"Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term follow up of a multicentre longitudinal cohort. Arthritis Rheum. 2011;63:2495\u2013503.","journal-title":"Arthritis Rheum"},{"key":"580_CR52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaut.2005.08.004","volume":"25","author":"M Krumbholz","year":"2005","unstructured":"Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun. 2005;25:298\u2013302.","journal-title":"J Autoimmun"},{"key":"580_CR53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, et al. Treatment of Churg\u2013Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586\u201394.","journal-title":"Arthritis Rheum"},{"key":"580_CR54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): clinical characteristics and long-term follow-up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65:270\u201381.","journal-title":"Arthritis Rheum"},{"key":"580_CR55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545\u201353. This paper provides useful tools for an effective individual management of patients with eosinophilic granulomatosis with polyangiitis.","journal-title":"Eur J Intern Med"},{"key":"580_CR56","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V, et al. Churg\u2013Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:686\u201393.","journal-title":"Arthritis Rheum"},{"key":"580_CR57","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/rheumatology\/36.12.1290","volume":"35","author":"M Gayraud","year":"1997","unstructured":"Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg\u2013Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol. 1997;35:1290\u20137.","journal-title":"Br J Rheumatol"},{"key":"580_CR58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/BOR.0b013e3280119854","volume":"19","author":"C Pagnoux","year":"2007","unstructured":"Pagnoux C, Guilpain P, Guillevin L. Churg\u2013Strauss syndrome. Curr Opin Rheumatol. 2007;19:25\u201332.","journal-title":"Curr Opin Rheumatol"},{"issue":"6 Suppl 36","key":"580_CR59","first-page":"S52","volume":"22","author":"C Metzler","year":"2004","unstructured":"Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S52\u201361.","journal-title":"Clin Exp Rheumatol"},{"issue":"1 Suppl 70","key":"580_CR60","first-page":"S62","volume":"30","author":"K Herrmann","year":"2012","unstructured":"Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S62\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"580_CR61","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","volume":"26","author":"R Cartin-Ceba","year":"2011","unstructured":"Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg\u2013Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26:2865\u201371.","journal-title":"Nephrol Dial Transplant"},{"key":"580_CR62","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, FerraroAJ CAN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum. 2009;60:2156\u201368.","journal-title":"Arthritis Rheum"},{"key":"580_CR63","doi-asserted-by":"crossref","unstructured":"Thiel J, Hassler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15:R133. Demonstration that B cell-depleting therapy with rituximab is effective in ANCA-positive eosinophilic granulomatosis with polyangiitis.","DOI":"10.1186\/ar4313"},{"key":"580_CR64","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","volume":"47","author":"RJ Pepper","year":"2008","unstructured":"Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47:1104\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"580_CR65","author":"AJ Mohammad","year":"2014","unstructured":"Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2014. doi: 10.1136\/annrheumdis-2014-206095 . Rituximab induced a high rate of clinical improvement and reduced requirement of prednisolone.","journal-title":"Ann Rheum Dis"},{"key":"580_CR66","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1136\/ard.2003.015453","volume":"63","author":"MG Danieli","year":"2004","unstructured":"Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg\u2013Strauss syndrome. Ann Rheum Dis. 2004;63:1649\u201354.","journal-title":"Ann Rheum Dis"},{"key":"580_CR67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","volume":"129","author":"E Tatsis","year":"1998","unstructured":"Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg\u2013Strauss syndrome. Ann Intern Med. 1998;129:370\u20134.","journal-title":"Ann Intern Med"},{"issue":"9842","key":"580_CR68","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"key":"580_CR69","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336\u201343.","journal-title":"J Allergy Clin Immunol"},{"key":"580_CR70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg\u2013Strauss syndrome. Ann Intern Med. 2011;155:341\u20133.","journal-title":"Ann Intern Med"},{"key":"580_CR71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000103228","volume":"144","author":"P Giavina-Bianchi","year":"2007","unstructured":"Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007;144:155\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"580_CR72","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","volume":"360","author":"JMM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin JMM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Sch\u00f6nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197\u2013202.","journal-title":"Lancet"},{"key":"580_CR73","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/adc.2005.077743","volume":"90","author":"M Haroon","year":"2005","unstructured":"Haroon M. Should children with Henoch-Sch\u00f6nlein purpura and abdominal pain be treated with steroids? Arch Dis Child. 2005;90:1196\u20138.","journal-title":"Arch Dis Child"},{"key":"580_CR74","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2006.03.024","volume":"149","author":"J Ronkainen","year":"2006","unstructured":"Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Sch\u00f6nlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149:241\u20137.","journal-title":"J Pediatr"},{"key":"580_CR75","first-page":"1457","volume":"22","author":"J Dudley","year":"2007","unstructured":"Dudley J, Smith G, Llewellyn-Edwards A, Tizard E. Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Sch\u00f6nlein purpura nephritis. Pediatr Nephrol. 2007;22:1457.","journal-title":"Pediatr Nephrol"},{"key":"580_CR76","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/kisup.2012.23","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO. Clinical Practice Guideline for Glomerulonephritis. Chapter 10: immunoglobulin a nephropathy. Kidney Int Suppl. 2012;2:209\u201317.","journal-title":"Kidney Int Suppl"},{"key":"580_CR77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00467-010-1723-7","volume":"26","author":"JM Park","year":"2011","unstructured":"Park JM, Won SC, Shin JI, Yim H, Pai KS. Cyclosporin A therapy for Henoch-Sch\u00f6nlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol. 2011;26:411\u20137.","journal-title":"Pediatr Nephrol"},{"key":"580_CR78","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00467-011-2057-9","volume":"27","author":"Y Du","year":"2012","unstructured":"Du Y, Hou L, Zhao C, Han M, Wu Y. Treatment of children with Henoch-Sch\u00f6nlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol. 2012;27:765\u201371.","journal-title":"Pediatr Nephrol"},{"key":"580_CR79","first-page":"1802","volume":"25","author":"Y Fuentes","year":"2010","unstructured":"Fuentes Y, Valverde S, Valesquez-Jones L. Comparison of azathioprine vs mofetil mycophenolate for Henoch-Sch\u00f6nlein nephritis treatment. Pediatr Nephrol. 2010;25:1802.","journal-title":"Pediatr Nephrol"},{"key":"580_CR80","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/ndt\/gfg617","volume":"19","author":"Y Kawasaki","year":"2004","unstructured":"Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Sch\u00f6nlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant. 2004;19:858\u201364.","journal-title":"Nephrol Dial Transplant"},{"key":"580_CR81","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00467-003-1315-x","volume":"19","author":"P Tarshish","year":"2004","unstructured":"Tarshish P, Bernstein J, Edelmann Jr CM. Henoch-Sch\u00f6nlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol. 2004;19:51\u20136.","journal-title":"Pediatr Nephrol"},{"key":"580_CR82","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpeds.2008.12.049","volume":"155","author":"KJ Donnithorne","year":"2009","unstructured":"Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, et al. Rituximab therapy for severe refractory chronic Henoch-Sch\u00f6nlein purpura. J Pediatr. 2009;155:136\u20139.","journal-title":"J Pediatr"},{"key":"580_CR83","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/ndt\/gfr137","volume":"26","author":"E Pillebout","year":"2011","unstructured":"Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26:2044\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"580_CR84","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1755-6686.2013.12007.x","volume":"39","author":"A El-Husseini","year":"2013","unstructured":"El-Husseini A, Ahmed A, Sabucedo A, Fabulo E. Refractory Henoch-Sch\u00f6nlein purpura: atypical aetiology and management. J Ren Care. 2013;39:77\u201381. Evidence of the promising use of rituximab in patients with HSP who do not respond to conventional therapies.","journal-title":"J Ren Care"},{"key":"580_CR85","doi-asserted-by":"crossref","first-page":"619218","DOI":"10.1155\/2014\/619218","volume":"2014","author":"T Pindi Sala","year":"2014","unstructured":"Pindi Sala T, Michot JM, Snanoudj R, Dollat M, Est\u00e8ve E, Marie B, et al. Successful outcome of a cortico-dependent Henoch-Sch\u00f6nlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218.","journal-title":"Case Rep Med"},{"key":"580_CR86","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s00296-012-2474-5","volume":"33","author":"F Maddi De","year":"2013","unstructured":"De Maddi F, Dinardo R, Buonocore MC, Dinardo M, Bartolomei B, Rigante D. Intravenous immunoglobulin in Henoch-Sch\u00f6nlein purpura complicated by cerebral hemorrhage. Rheumatol Int. 2013;33:2451\u20133.","journal-title":"Rheumatol Int"},{"key":"580_CR87","unstructured":"Stagnaro C, Cioffi E, Talarico R, Della Rossa A. Systemic vasculitides: a critical digest of the most recent literature. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-145-54. Overview of the most relevant studies regarding the epidemiology, pathogenesis and management of systemic vasculitis."},{"key":"580_CR88","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","volume":"119","author":"B Terrier","year":"2012","unstructured":"Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119:5996\u20136004.","journal-title":"Blood"},{"key":"580_CR89","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cath\u00e9bras P, et al. Safety and efficacy of rituximab in non-viral cryoglobulinemia vasculitis: data from the French autoimmunity and rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787\u201395.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"580_CR90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.autrev.2012.04.002","volume":"12","author":"T Lahmer","year":"2012","unstructured":"Lahmer T, Heemann U. Anti-glomerular basement membrane antibody disease: a rare autoimmune disorder affecting the kidney and the lung. Autoimmun Rev. 2012;12:169\u201373.","journal-title":"Autoimmun Rev"},{"key":"580_CR91","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","volume":"134","author":"JB Levy","year":"2001","unstructured":"Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033\u201342.","journal-title":"Ann Intern Med"},{"key":"580_CR92","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.autrev.2014.11.006","volume":"14","author":"A Greco","year":"2015","unstructured":"Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G, et al. Goodpasture's syndrome: a clinical update. Autoimmun Rev. 2015;14:246\u201353.","journal-title":"Autoimmun Rev"},{"key":"580_CR93","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2015.04.003","volume":"60","author":"M Touzot","year":"2015","unstructured":"Touzot M, Poisson J, Faguer S, Ribes D, Cohen P, Geffray L, et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun. 2015;60:74\u20139. Demostration of rituximab efficacy as additional and\/or alternative therapy in the induction treatment of anti-glomerular basement membrane disease.","journal-title":"J Autoimmun"},{"key":"580_CR94","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11926-009-0060-y","volume":"11","author":"LJ Jara","year":"2009","unstructured":"Jara LJ, Navarro C, Medina G, Vera-Lastra O, Saavedra MA. Hypocomplementemic urticarial vasculitis syndrome. Curr Rheumatol Rep. 2009;11:410\u20135.","journal-title":"Curr Rheumatol Rep"},{"key":"580_CR95","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","volume":"67","author":"M Jachiet","year":"2015","unstructured":"Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015;67:527\u201334. The present study includes the largest series of patients with hypocomplementemic urticarial vasculitis reported so far in the literature.","journal-title":"Arthritis Rheumatol"},{"key":"580_CR96","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00296-009-1337-1","volume":"30","author":"D Rigante","year":"2010","unstructured":"Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int. 2010;30:841\u20136.","journal-title":"Rheumatol Int"},{"key":"580_CR97","first-page":"301","volume":"11","author":"G Rosa De","year":"2007","unstructured":"De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-016-0580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-016-0580-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-016-0580-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T21:58:00Z","timestamp":1567807080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-016-0580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s11926-016-0580-1","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]},"article-number":"36"}}